Actilyse Contraindications

Generally, in all indications Actilyse should not be administered to patients with known hypersensitivity to the active substance alteplase, gentamicin (a trace residue from the manufacturing process) or to any of the excipients listed in Description.
Contraindications in acute myocardial infarction, acute massive pulmonary embolism and acute ischaemic stroke: Actilyse is contraindicated in cases where there is a high risk of haemorrhage such as: significant bleeding disorder at present or within the past 6 months; known haemorrhagic diathesis; patients receiving effective oral anticoagulant treatment, e.g. warfarin sodium (INR > 1.3) (see Precautions); manifest or recent severe or dangerous bleeding; known history of or suspected intracranial haemorrhage; suspected subarachnoid haemorrhage or condition after subarachnoid haemorrhage from aneurysm; any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery); recent (less than 10 days) traumatic external heart massage, obstetrical delivery, recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein puncture); severe uncontrolled arterial hypertension; bacterial endocarditis, pericarditis; acute pancreatitis; documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial-aneurysm, arterial/venous malformations; neoplasm with increased bleeding risk; severe liver disease, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis; major surgery or significant trauma in past 3 months.
Additional contraindications in acute myocardial infarction: any known history of haemorrhagic stroke or stroke of unknown origin; known history of ischaemic stroke or transient ischaemic attack (TIA) in the preceding 6 months except current acute ischaemic stroke within 4.5 hours.
Additional contraindications in acute massive pulmonary embolism: any known history of haemorrhagic stroke or stroke of unknown origin; known history of ischaemic stroke or transient ischaemic attack (TIA) in the preceding 6 months except current acute ischaemic stroke within 4.5 hours.
Additional contraindications in acute ischaemic stroke: symptoms of ischaemic attack beginning more than 4.5 hours prior to infusion start or symptoms for which the onset time is unknown and could potentially be more than 4.5 hours ago (see Pharmacology: Pharmacodynamics under Actions); minor neurological deficit or symptoms rapidly improving before start of infusion; severe stroke as assessed clinically (e.g. NIHSS>25) and/or by appropriate imaging techniques; seizure at onset of stroke; evidence of intracranial haemorrhage (ICH) on the CT-scan; symptoms suggestive of subarachnoid haemorrhage, even if CT-scan is normal; administration of heparin within the previous 48 hours and a thromboplastin time exceeding the upper limit of normal for laboratory; patients with any history of prior stroke and concomitant diabetes; prior stroke within the last 3 months; platelet count of below 100,000/mm³; systolic blood pressure > 185 mm Hg or diastolic BP > 110 mm Hg, or aggressive management (intravenous pharmacotherapy) necessary to reduce BP to these limits; blood glucose < 50 mg/dl or > 400 mg/dl (< 2.8mM or > 22.2mM).
Use in Children: Actilyse is not indicated for the treatment of acute ischaemic stroke in children under 16 years of age (for adolescents ≥ 16 years of age see Precautions).